Genetic Variation and Exposure Related Risk Estimation: Will Toxicology Enter a New Era? DNA Repair and Cancer as a Paradigm
暂无分享,去创建一个
[1] M. Bleavins,et al. Pharmacogenetic application in drug development and clinical trials. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[2] D. Cheo,et al. Cancer predisposition in mutant mice defective in multiple genetic pathways: uncovering important genetic interactions. , 2001, Mutation research.
[3] G. Boivin,et al. Enhanced Tumor Formation in Mice Heterozygous for Blm Mutation , 2002, Science.
[4] K. Buetow,et al. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. , 2001, Biochimica et biophysica acta.
[5] R C Garner,et al. The role of DNA adducts in chemical carcinogenesis. , 1998, Mutation research.
[6] C. Harris,et al. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Ingelman-Sundberg,et al. Unravelling the functional genomics of the human CYP2D6 gene locus. , 2001, Pharmacogenetics.
[8] E. Mark,et al. Polymorphisms in the Dna Repair Genes Xrcc1 and Ercc2 and Biomarkers of Dna Damage in Human Blood Mononuclear Cells Cross-complementing Group 1) than in 399arg/arg Carriers of Breaks following Base Excision Repair (ber) Resulting From , 2022 .
[9] P Vineis,et al. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. , 2000, Journal of the National Cancer Institute.
[10] Hongbing Shen,et al. Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. , 2002, Carcinogenesis.
[11] D. Boomsma,et al. Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes. , 1999, Journal of the National Cancer Institute.
[12] H. Norppa,et al. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. , 2000, Cancer research.
[13] L. Povirk,et al. DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. , 1996, Mutation research.
[14] B. Delaney. Dyspepsia management in the millennium: to test and treat or not? , 2003, Gut.
[15] H. Morgenstern,et al. Environmental tobacco smoking, mutagen sensitivity, and head and neck squamous cell carcinoma. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[16] P. Vineis. Molecular epidemiology: Low‐dose carcinogens and genetic susceptibility , 1997, International journal of cancer.
[17] P. Hsieh,et al. Molecular mechanisms of DNA mismatch repair. , 2001, Mutation research.
[18] C. Wolf,et al. Science, medicine, and the future: Pharmacogenetics. , 2000, BMJ.
[19] I. M. Jones,et al. Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. , 2003, Mutation research.
[20] Lee Bennett,et al. Genomic interrogation of mechanism(s) underlying cellular responses to toxicants. , 2002, Toxicology.
[21] H. Mohrenweiser,et al. Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. , 2001, Carcinogenesis.
[22] R. Hammer,et al. Heterozygosity for the mouse Apex gene results in phenotypes associated with oxidative stress. , 2001, Cancer research.
[23] D. Purdie,et al. Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer , 2002, Nature Genetics.
[24] Warren C. Lathe,et al. Prediction of deleterious human alleles. , 2001, Human molecular genetics.
[25] J. Moult,et al. SNPs, protein structure, and disease , 2001, Human mutation.
[26] A. Nafziger,et al. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. , 2002, The American journal of medicine.
[27] B. Ponder. Cancer genetics , 2001, Nature.
[28] T. Zacharewski,et al. Genetics and Susceptibility to Toxic Chemicals: Do You (or Should You) Know Your Genetic Profile? , 2003, Journal of Pharmacology and Experimental Therapeutics.
[29] W. Kalow. Pharmacogenetics, pharmacogenomics, and pharmacobiology , 2001, Clinical pharmacology and therapeutics.
[30] T. Sellers,et al. Lung cancer detection and prevention: evidence for an interaction between smoking and genetic predisposition. , 1992, Cancer research.
[31] P. Bork,et al. Human non-synonymous SNPs: server and survey. , 2002, Nucleic acids research.
[32] I. M. Jones,et al. Elevated frequencies of hypoxanthine phosphoribosyltransferase lymphocyte mutants are detected in Russian liquidators 6 to 10 years after exposure to radiation from the Chernobyl nuclear power plant accident. , 1999, Mutation research.
[33] S. Haas,et al. Transgenic systems in studies on genotoxicity of alkylating agents: critical lesions, thresholds and defense mechanisms. , 1998, Mutation research.
[34] T. Beaty,et al. Genomewide screen and identification of gene-gene interactions for asthma-susceptibility loci in three U.S. populations: collaborative study on the genetics of asthma. , 2001, American journal of human genetics.
[35] B. Trock,et al. DNA Repair as A Susceptibility Factor in Chronic Diseases in Human Populations , 1999 .
[36] M. King,et al. Insights into the functions of BRCA1 and BRCA2. , 2000, Trends in genetics : TIG.
[37] I. M. Jones,et al. Three Somatic Genetic Biomarkers and Covariates in Radiation-Exposed Russian Cleanup Workers of the Chernobyl Nuclear Reactor 6–13 Years after Exposure , 2002, Radiation research.
[38] Richard D. Wood,et al. Human DNA Repair Genes , 2001, Science.
[39] P. Walsh. Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. , 2002, The Journal of urology.
[40] J M Silva,et al. Chromosomal aberrations in lymphocytes from car painters. , 1996, Mutation research.
[41] I. M. Jones,et al. Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[42] F. Hossler,et al. PERIPHERAL BLOOD -- Lymphocyte , 1998 .
[43] M. Spitz,et al. Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes. , 2002, Mutation research.
[44] D. Easton,et al. Cancer mortality in relatives of women with breast cancer: The OPCS study , 1996, International journal of cancer.
[45] D. Flockhart,et al. Cytochrome P450 3A pharmacogenetics: the road that needs traveled , 2003, The Pharmacogenomics Journal.
[46] M. Oscarson. Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine , 2003, Clinical chemistry and laboratory medicine.
[47] U. Vogel,et al. Polymorphisms of the DNA repair gene XPD: correlations with risk of basal cell carcinoma revisited. , 2001, Carcinogenesis.
[48] Larry Borish,et al. 5. Genetics of hypersensitivity. , 2003, The Journal of allergy and clinical immunology.
[49] D. Easton,et al. Cancer mortality in relatives of women with ovarian cancer: The OPCS study , 1996, International journal of cancer.
[50] David H Phillips,et al. DNA adducts as markers of exposure and risk. , 2005, Mutation research.
[51] J. Hoeijmakers. Genome maintenance mechanisms for preventing cancer , 2001, Nature.
[52] G. Petersen,et al. Familial aggregation: sorting susceptibility from shared environment. , 2000, Journal of the National Cancer Institute.
[53] Howard L McLeod,et al. Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.
[54] P. Vineis,et al. Studies of DNA repair and human cancer: an update , 2002 .
[55] W. Tan,et al. Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population , 2003, International journal of cancer.
[56] Gupta Rc,et al. Background DNA damage for endogenous and unavoidable exogenous carcinogens: a basis for spontaneous cancer incidence? , 1999 .
[57] D. Christiani,et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[58] M. Tockman,et al. Gene-environment interactions between the codon 194 polymorphism of XRCC1 and antioxidants influence lung cancer risk. , 2003, Anticancer research.
[59] C. Ulrich,et al. Polymorphisms in DNA repair genes and associations with cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[60] M. Spitz,et al. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. , 2003, Carcinogenesis.
[61] I. M. Jones,et al. Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? , 1998, Mutation research.
[62] M. Spitz,et al. Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. , 1998, Journal of the National Cancer Institute.
[63] D. Cheo,et al. Cancer predisposition in mutant mice defective in the XPC DNA repair gene. , 1999, Progress in experimental tumor research.
[64] M Schwab,et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. , 2001, Pharmacogenetics.
[65] F. Perera. Molecular epidemiology: on the path to prevention? , 2000, Journal of the National Cancer Institute.
[66] N. Cox. Challenges in identifying genetic variation affecting susceptibility to type 2 diabetes: examples from studies of the calpain-10 gene. , 2001, Human molecular genetics.
[67] P. Lemotte,et al. DNA damage induced in human diploid cells by decay of incorporated radionuclides. , 1984, Cancer research.
[68] G. H. Bush,et al. Pharmacogenetics , 1968 .
[69] R. Kucherlapati,et al. Haploinsufficiency of Flap endonuclease (Fen1) leads to rapid tumor progression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[70] H. Bernstein,et al. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. , 2002, Mutation research.
[71] D. Evans,et al. Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer? , 1999, American journal of human genetics.
[72] H. Norppa,et al. Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). , 1998, Cancer research.
[73] V. Slavkovich,et al. DNA repair gene XPD and susceptibility to arsenic-induced hyperkeratosis. , 2003, Toxicology letters.
[74] R. Gupta,et al. Background DNA damage for endogenous and unavoidable exogenous carcinogens: a basis for spontaneous cancer incidence? , 1999, Mutation research.
[75] P. Doris. Hypertension Genetics, Single Nucleotide Polymorphisms, and the Common Disease:Common Variant Hypothesis , 2002, Hypertension.
[76] R. Weinshilboum. Inheritance and drug response. , 2003, The New England journal of medicine.
[77] A. Daly,et al. Pharmacogenetics of the major polymorphic metabolizing enzymes , 2003, Fundamental & clinical pharmacology.
[78] D. Phillips,et al. Polymorphisms of the GSTP1 and GSTM1 genes and PAH‐DNA adducts in human mononuclear white blood cells , 2000, Environmental and molecular mutagenesis.
[79] S. Henikoff,et al. Accounting for human polymorphisms predicted to affect protein function. , 2002, Genome research.
[80] D. Brenner,et al. Atm heterozygous mice are more sensitive to radiation-induced cataracts than are their wild-type counterparts , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[81] K. Tanaka,et al. Importance of DNA repair in carcinogenesis: evidence from transgenic and gene targeting studies. , 2001, Mutation research.
[82] J. Carlquist,et al. Cardiovascular Pharmacogenomics: Current Status, Future Prospects , 2003, Journal of cardiovascular pharmacology and therapeutics.
[83] L. Brooks,et al. A DNA polymorphism discovery resource for research on human genetic variation. , 1998, Genome research.
[84] N. Risch. Searching for genetic determinants in the new millennium , 2000, Nature.
[85] H. Wallin,et al. Psoriasis patients with basal cell carcinoma have more repair-mediated DNA strand-breaks after UVC damage in lymphocytes than psoriasis patients without basal cell carcinoma. , 2000, Cancer letters.
[86] G. Siest,et al. Pharmacogenomics of Drugs Affecting the Cardiovascular System , 2003, Clinical chemistry and laboratory medicine.
[87] K. Turteltaub,et al. Methods of Dna Adduct Determination and Their Application to Testing Compounds for Genotoxicity , 2022 .
[88] R. Fanelli,et al. Carcinogen-DNA adducts as tools in risk assessment. , 1999, Advances in experimental medicine and biology.
[89] W. Evans,et al. Pharmacogenomics: marshalling the human genome to individualise drug therapy , 2003, Gut.
[90] R. Patel,et al. DNA repair proficiency in breast cancer patients and their first‐degree relatives , 1997, International journal of cancer.
[91] K. Lohman,et al. Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. , 2003, Cancer letters.
[92] T. Lindahl. Instability and decay of the primary structure of DNA , 1993, Nature.
[93] I. M. Jones,et al. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. , 1998, Cancer research.
[94] J. Ihle. The Challenges of Translating Knockout Phenotypes into Gene Function , 2000, Cell.
[95] D. Kuijpers,et al. Basal Cell Carcinoma , 2002, American journal of clinical dermatology.
[96] R. Weinshilboum,et al. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[97] M. Spitz,et al. A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung carcinoma cases and controls , 1998, Cancer.
[98] Bruce M Psaty,et al. Genomics and Medicine: Distraction, Incremental Progress, or the Dawn of a New Age? , 2003, Annals of Internal Medicine.
[99] M. Nair,et al. DNA repair proficiency: a potential marker for identification of high risk members in breast cancer families. , 1998, Cancer letters.
[100] N. Risch,et al. The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[101] J. Hopper,et al. Genetic epidemiology of female breast cancer. , 2001, Seminars in cancer biology.
[102] F. Perera,et al. DNA adducts as markers of exposure to carcinogens and risk of cancer , 2000, International journal of cancer.
[103] D. Bell,et al. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. , 1999, Cancer research.
[104] K. Hemminki,et al. DNA adducts as a marker for cancer risk? , 2001, International journal of cancer.
[105] W. Kalow,et al. Pharmacogenetics and personalised medicine , 2002, Fundamental & clinical pharmacology.
[106] F. Perera,et al. Association between polycyclic aromatic hydrocarbon-DNA adduct levels in maternal and newborn white blood cells and glutathione S-transferase P1 and CYP1A1 polymorphisms. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[107] S. Henikoff,et al. Predicting deleterious amino acid substitutions. , 2001, Genome research.
[108] Eric Boerwinkle,et al. Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. , 2003, Pharmacogenomics.
[109] D. Cheo,et al. Ultraviolet B radiation-induced skin cancer in mice defective in the Xpc, Trp53, and Apex (HAP1) genes: genotype-specific effects on cancer predisposition and pathology of tumors. , 2000, Cancer research.
[110] G. Orphanides. Toxicogenomics: challenges and opportunities. , 2003, Toxicology letters.
[111] I. M. Jones,et al. Human in vivo somatic mutation measured at two loci: individuals with stably elevated background erythrocyte glycophorin A (gpa) variant frequencies exhibit normal T-lymphocyte hprt mutant frequencies. , 1998, Mutation research.
[112] K. Fidelis,et al. Functional characterization of Ape1 variants identified in the human population. , 2000, Nucleic acids research.
[113] M. Daly,et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms , 2001, Nature.
[114] E. Friedberg,et al. DNA Repair and Mutagenesis , 2006 .
[115] Klaus Lindpaintner,et al. Pharmacogenetics and the future of medical practice. , 2002, Journal of molecular medicine.
[116] A. Povey. DNA Adducts: Endogenous and Induced , 2000, Toxicologic pathology.
[117] W. Lutz. Dose-response relationships in chemical carcinogenesis reflect differences in individual susceptibility. Consequences for cancer risk assessment, extrapolation, and prevention , 1999, Human & experimental toxicology.
[118] D. Schild,et al. Homologous recombinational repair of DNA ensures mammalian chromosome stability. , 2001, Mutation research.